ImmunityBio, Inc.IBRXEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Cambridge Equities, LP | 39.00% | 261.7M | ▼ -0.20pp | 2024-01-04 |
Insider Transactions
Net 90d: +$22.16M · buys $25.00M / sells $2.84MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-31 | SOON-SHIONG PATRICK | See remarks | Conversion | 4.61M | $5.43 | $25.00M |
| 2026-02-24 | Simon Barry J. | Director | Sell (open market) | 75.0K | $12.01 | $900.8K |
| 2026-02-23 | Christobel Selecky | Director | Option exercise | 25.0K | $2.98 | $74.5K |
| 2026-02-23 | Christobel Selecky | Director | Sell (open market) | 25.0K | $10.00 | $250.0K |
| 2026-02-23 | Simon Barry J. | Director | Sell (open market) | 165.0K | $10.25 | $1.69M |
| 2026-02-22 | SOON-SHIONG PATRICK | See remarks | Option exercise | 114.3K | $0.00 | $0 |
| 2026-02-22 | Sachs David C. | Chief Financial Officer | Option exercise | 40.6K | $0.00 | $0 |
| 2026-02-22 | Simon Barry J. | Director | Option exercise | 15.2K | $0.00 | $0 |
| 2026-02-22 | Richard Adcock | CEO & President | Option exercise | 152.4K | $0.00 | $0 |
| 2026-02-22 | LAUER REGAN J | Chief Accounting Officer | Option exercise | 4.1K | $0.00 | $0 |
1–10 of 10